Datacise® Technology Platform

Data has never been easier to visualize.

The Datacise Dashboards really are a major step forward in exploring our Safety data.
clinical project manager
Biotechnology Sponsor (Neurology)

Datacise® is an innovative, cloud-based technology platform, that aggregates and mines data to provide real-time insights for our Sponsors.

With this secure, scalable data science platform, Datacise allows Sponsors to immediately and analyze and visualize clinical data, Real-World Data (RWD) and data from other data sources through three advanced applications: Curate, Analyze, and Explore.  
 
All applications in the Datacise suite are fully integrated with the ability to use together or as stand-alone applications.

Click to learn more about Biometrics solutions that accompany this technology.

Datacise CURATE

Datacise CURATE is a flexible cloud application for the collection and aggregation of clinical data through a variety of data mapping or abstraction methods. This scalable platform simplifies the extract, load, transform (ETL) process to easily ingest structured and unstructured data from any source.

Typical Sponsor use cases for Datacise CURATE include:

  • Extract and abstract structured and unstructured data via API (application programming interfaces) or other methods
  • Build databases, including data lakes, data warehouses, and other advanced data storage structures (i.e., network graphs)
  • Harmonize data through advance pattern matching and the use of  external ontologies, including WHO Drug, MedDRA, CDISC controlled terminology, and other custom dictionaries
  • Perform data and image processing in preparation for further analysis or anonymization (DICOM images)
Datacise ANALYZE

Datacise ANALYZE supports advanced analytical needs for RWD and other data. This includes support of machine learning (ML), natural language processing (NLP) and network graphs. Several state-of-the art data science programming languages are used to analyze data, including Python, R, and  others. ANALYZE is fully integrated with other Datacise applications. Data presentations include advanced visualization features of R Shiny and JavaScript libraries for data-driven documents.

Typical Sponsor use cases for Datacise Explore include:

  • Produce simulations and scenario planning
  • Perform trend identification across disparate data, including a focus on subsets (cluster analyses)
  • Analyze data from unstructured sources, using ML and NLP
  • Ability to utilize high-performance computing as necessary for analysis
Datacise EXPLORE

Datacise EXPLORE provides integrated data visualizations and dashboards to support analysis, review, and speed decision-making. This includes automated data extraction via application programming interfaces (APIs), providing direct access to a wide variety of integrated data and automated file transfers of SAS datasets and other file types. Data refreshes may be scheduled on a regular basis, and users can select between one of the numerous standards, pre-built dashboards or custom data visualizations, depending on need.

Typical Sponsor use cases for Datacise EXPLORE include:

  • DSMB (Data Safety Monitoring Boards) and Adjudication meetings including dashboards to augment static tables and listings
  • Patient profiles to aid in ongoing safety reviews and assessments
  • Dashboards for medical device and wearables data
  • In-process data reviews by clinical teams or data managers to ensure data accuracy
  • A tool used in the application of risk–based monitoring (RBM) strategies
  • Safety surveillance signal detection, using social media and regulatory data sources (i.e., FAERS)

Learn pharmaceutical industry best practices for developing practical data visualizations, tips on identifying and avoiding common pitfalls, interactive dashboards from initial discovery through UAT (User Acceptance Testing) and validation strategies, and the importance of understanding the intended audience and planned use for data visualizations.

Suggested For You

webinar

September 26th, 2024

Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance

regulatory intelligence

August 27th, 2024

Recent Guidance on Diversity Action Planning

regulatory intelligence

August 26th, 2024

Oncology Programs at the FDA

regulatory intelligence

August 26th, 2024

Three Key Take Reflections on the Recent Donanemab Approval

webinar

September 12th, 2024

No Stone Unturned: Optimizing the Use of Expedited Pathways and Oncology Center of Excellence Programs to Optimize Drug Development in Oncology

regulatory intelligence

August 9th, 2024

FDA Updates 2024 Language Access Plan

regulatory intelligence

August 3rd, 2024

EMA Launches New Pilot Program for Orphan Medical Devices

perspectives

July 30th, 2024

The Critical Role of Quality Control (QC) – Medical Writing and Beyond

regulatory intelligence

July 26th, 2024

Key Decision Points for Recent Oncology Approvals

regulatory intelligence

July 24th, 2024

Comments Open for Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products

perspectives

July 23rd, 2024

PSI 2024 Ignited Conversations on External Data Sources, Requirements for Estimands, and Bayesian Methodology for Statisticians in Pharma

news

July 17th, 2024

Industry Veteran Ben Dudley Joins MMS as Chief Commercial Officer (CCO) to Drive Continued Growth for the Data-focused Clinical Research Organization